hypericin has been researched along with Glioma in 26 studies
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypericin is a potent inhibitor of glioma growth in vitro." | 9.15 | A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. ( Appley, AJ; Cabana, BE; Chen, TC; Couldwell, WT; Forsyth, PA; Hinton, DR; Spence, AM; Stillerman, CB; Surnock, AA; Tobia, AJ, 2011) |
| "The viability of U87 MG glioma cells in the presence of rottlerin and hypericin was assessed by MTT assay and flow cytometry in the absence and presence of light." | 7.85 | Synergism between PKCδ regulators hypericin and rottlerin enhances apoptosis in U87 MG glioma cells after light stimulation. ( Horvath, D; Huntosova, V; Miskovsky, P; Misuth, M, 2017) |
| " We show the localization of Bax and Bak in U-87 MG human glioma cells incubated with photosensitizer hypericin (Hyp) before and after photodynamic action." | 7.79 | Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action. ( Balogová, L; Dzurová, L; Maslaňáková, M; Miškovský, P; Stroffeková, K, 2013) |
| "In a syngeneic subcutaneous glioma mouse model we investigated the time dependent hypericin (HYP) uptake in malignant tumor tissue by microendoscopically fluorescence measurements." | 7.79 | Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model. ( Ehrhardt, A; Feigl, GC; Göbel, W; Mayer, D; Naumann, U; Noell, S; Ritz, R; Serifi, D, 2013) |
| "In five patients with a recurrence of a malignant glioma a newly developed water soluble formulation of hypericin was given intravenously (0." | 7.78 | Hypericin for visualization of high grade gliomas: first clinical experience. ( Bornemann, A; Daniels, R; Dietz, K; Feigl, GC; Mayer, D; Noell, S; Ramina, K; Ritz, R; Schmidt, V; Strauss, WS; Tatagiba, M, 2012) |
| " Hypericin (HY) exhibit high phototoxicity to malignant cells and accumulates to a higher extent in glioblastoma cells as compared to neurons." | 7.74 | Photodynamic therapy of malignant glioma with hypericin: comprehensive in vitro study in human glioblastoma cell lines. ( Dietz, K; Ritz, R; Roser, F; Schenk, M; Strauss, WS; Tatagiba, M; Wein, HT, 2007) |
| " We studied the interrelation of proliferation and migration in the presence of different protein-kinase-C(PKC) inhibitors (TAM, staurosporine, hypericin) in 2 glioma cell lines." | 7.70 | Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation. ( Giese, A; Puchner, MJ, 2000) |
| "Hypericin and tamoxifen are experimental agents for the adjuvant chemotherapy of malignant glioma." | 7.69 | Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. ( Bremen, D; Grimmel, C; Krajewski, S; Reed, JC; Schabet, M; Trepel, M; Weller, M, 1997) |
| "The effect of hypericin, an antiviral drug and a potent protein kinase C (PKC) inhibitor, on glioma cell invasion was investigated in vitro." | 7.69 | Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. ( Couldwell, WT; Hinton, DR; Law, RE; Zhang, W, 1997) |
| "Hypericin (Hyp) is a hydrophobic natural photosensitizer that is considered to be a promising molecule for photodynamic treatment of tumor cells and photo-diagnosis of early epithelial cancers." | 5.38 | Cell death response of U87 glioma cells on hypericin photoactivation is mediated by dynamics of hypericin subcellular distribution and its aggregation in cellular organelles. ( Dzurova, L; Huntosova, V; Jakusova, V; Miskovsky, P; Nadova, Z; Sureau, F, 2012) |
| "Malignant gliomas are diffuse infiltrative growing tumors with a poor prognosis despite treatment with a combination of surgery, radiotherapy and chemotherapy." | 5.37 | Selective enrichment of hypericin in malignant glioma: pioneering in vivo results. ( Mayer, D; Noell, S; Ritz, R; Strauss, WS; Tatagiba, MS, 2011) |
| "Three patients suffered from an anaplastic astrocytoma, WHO grade III, nine had a glioblastoma, WHO grade IV." | 5.35 | Hypericin uptake: a prognostic marker for survival in high-grade glioma. ( Bornemann, A; Dietz, K; Duffner, F; Müller, M; Ritz, R; Roser, F; Tatagiba, M, 2008) |
| "Hypericin is a potent inhibitor of glioma growth in vitro." | 5.15 | A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. ( Appley, AJ; Cabana, BE; Chen, TC; Couldwell, WT; Forsyth, PA; Hinton, DR; Spence, AM; Stillerman, CB; Surnock, AA; Tobia, AJ, 2011) |
| "The viability of U87 MG glioma cells in the presence of rottlerin and hypericin was assessed by MTT assay and flow cytometry in the absence and presence of light." | 3.85 | Synergism between PKCδ regulators hypericin and rottlerin enhances apoptosis in U87 MG glioma cells after light stimulation. ( Horvath, D; Huntosova, V; Miskovsky, P; Misuth, M, 2017) |
| " We show the localization of Bax and Bak in U-87 MG human glioma cells incubated with photosensitizer hypericin (Hyp) before and after photodynamic action." | 3.79 | Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action. ( Balogová, L; Dzurová, L; Maslaňáková, M; Miškovský, P; Stroffeková, K, 2013) |
| "In a syngeneic subcutaneous glioma mouse model we investigated the time dependent hypericin (HYP) uptake in malignant tumor tissue by microendoscopically fluorescence measurements." | 3.79 | Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model. ( Ehrhardt, A; Feigl, GC; Göbel, W; Mayer, D; Naumann, U; Noell, S; Ritz, R; Serifi, D, 2013) |
| "In five patients with a recurrence of a malignant glioma a newly developed water soluble formulation of hypericin was given intravenously (0." | 3.78 | Hypericin for visualization of high grade gliomas: first clinical experience. ( Bornemann, A; Daniels, R; Dietz, K; Feigl, GC; Mayer, D; Noell, S; Ramina, K; Ritz, R; Schmidt, V; Strauss, WS; Tatagiba, M, 2012) |
| " Hypericin (HY) exhibit high phototoxicity to malignant cells and accumulates to a higher extent in glioblastoma cells as compared to neurons." | 3.74 | Photodynamic therapy of malignant glioma with hypericin: comprehensive in vitro study in human glioblastoma cell lines. ( Dietz, K; Ritz, R; Roser, F; Schenk, M; Strauss, WS; Tatagiba, M; Wein, HT, 2007) |
| " We studied the interrelation of proliferation and migration in the presence of different protein-kinase-C(PKC) inhibitors (TAM, staurosporine, hypericin) in 2 glioma cell lines." | 3.70 | Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation. ( Giese, A; Puchner, MJ, 2000) |
| "Hypericin and tamoxifen are experimental agents for the adjuvant chemotherapy of malignant glioma." | 3.69 | Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. ( Bremen, D; Grimmel, C; Krajewski, S; Reed, JC; Schabet, M; Trepel, M; Weller, M, 1997) |
| "The effect of hypericin, an antiviral drug and a potent protein kinase C (PKC) inhibitor, on glioma cell invasion was investigated in vitro." | 3.69 | Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. ( Couldwell, WT; Hinton, DR; Law, RE; Zhang, W, 1997) |
| "Hypericin (Hyp) is a naturally occurring compound used as photosensitizer in photodynamic therapy and diagnosis." | 1.51 | Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels. ( Huntosova, V; Kozar, T; Stroffekova, K; Tomkova, S, 2019) |
| "Hypericin (Hyp) is a hydrophobic natural photosensitizer that is considered to be a promising molecule for photodynamic treatment of tumor cells and photo-diagnosis of early epithelial cancers." | 1.38 | Cell death response of U87 glioma cells on hypericin photoactivation is mediated by dynamics of hypericin subcellular distribution and its aggregation in cellular organelles. ( Dzurova, L; Huntosova, V; Jakusova, V; Miskovsky, P; Nadova, Z; Sureau, F, 2012) |
| "Malignant gliomas are diffuse infiltrative growing tumors with a poor prognosis despite treatment with a combination of surgery, radiotherapy and chemotherapy." | 1.37 | Selective enrichment of hypericin in malignant glioma: pioneering in vivo results. ( Mayer, D; Noell, S; Ritz, R; Strauss, WS; Tatagiba, MS, 2011) |
| "Three patients suffered from an anaplastic astrocytoma, WHO grade III, nine had a glioblastoma, WHO grade IV." | 1.35 | Hypericin uptake: a prognostic marker for survival in high-grade glioma. ( Bornemann, A; Dietz, K; Duffner, F; Müller, M; Ritz, R; Roser, F; Tatagiba, M, 2008) |
| "Hypericin treatment (6." | 1.33 | Hypericin-an inhibitor of proteasome function. ( Fiebich, B; Pajonk, F; Scholber, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 15 (57.69) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Bassler, MC | 1 |
| Rammler, T | 1 |
| Wackenhut, F | 1 |
| Zur Oven-Krockhaus, S | 1 |
| Secic, I | 1 |
| Ritz, R | 6 |
| Meixner, AJ | 1 |
| Brecht, M | 1 |
| Stroffekova, K | 5 |
| Tomkova, S | 1 |
| Huntosova, V | 9 |
| Kozar, T | 2 |
| Misuth, M | 3 |
| Horvath, D | 4 |
| Miskovsky, P | 7 |
| Balogová, L | 2 |
| Maslaňáková, M | 2 |
| Dzurová, L | 4 |
| Noell, S | 3 |
| Feigl, GC | 2 |
| Serifi, D | 1 |
| Mayer, D | 3 |
| Naumann, U | 1 |
| Göbel, W | 1 |
| Ehrhardt, A | 1 |
| Petrovajova, D | 2 |
| Nadova, Z | 3 |
| Garg, AD | 1 |
| Vandenberk, L | 1 |
| Koks, C | 1 |
| Verschuere, T | 1 |
| Boon, L | 1 |
| Van Gool, SW | 1 |
| Agostinis, P | 1 |
| Verebova, V | 1 |
| Belej, D | 2 |
| Joniova, J | 3 |
| Jurasekova, Z | 1 |
| Stanicova, J | 1 |
| Hrivnak, S | 1 |
| Novotova, M | 2 |
| Nichtova, Z | 2 |
| Shibata, Y | 1 |
| Alvarez, L | 1 |
| Bryndzova, L | 1 |
| Jancura, D | 1 |
| Buriankova, L | 1 |
| Bonneau, S | 1 |
| Brault, D | 1 |
| Sureau, F | 3 |
| Strauss, WS | 3 |
| Tatagiba, MS | 1 |
| Couldwell, WT | 4 |
| Surnock, AA | 1 |
| Tobia, AJ | 1 |
| Cabana, BE | 1 |
| Stillerman, CB | 1 |
| Forsyth, PA | 1 |
| Appley, AJ | 1 |
| Spence, AM | 1 |
| Hinton, DR | 4 |
| Chen, TC | 1 |
| Daniels, R | 1 |
| Schmidt, V | 1 |
| Bornemann, A | 2 |
| Ramina, K | 1 |
| Dietz, K | 3 |
| Tatagiba, M | 3 |
| Jakusova, V | 1 |
| Pajonk, F | 1 |
| Scholber, J | 1 |
| Fiebich, B | 1 |
| Wein, HT | 1 |
| Schenk, M | 1 |
| Roser, F | 2 |
| Müller, M | 1 |
| Duffner, F | 1 |
| Gopalakrishna, R | 2 |
| He, S | 1 |
| Weiss, MH | 2 |
| Law, RE | 4 |
| Apuzzo, ML | 1 |
| Weller, M | 1 |
| Trepel, M | 1 |
| Grimmel, C | 1 |
| Schabet, M | 1 |
| Bremen, D | 1 |
| Krajewski, S | 1 |
| Reed, JC | 1 |
| Zhang, W | 2 |
| Anker, L | 1 |
| Pu, Q | 1 |
| Gundimeda, U | 1 |
| Miccoli, L | 1 |
| Beurdeley-Thomas, A | 1 |
| De Pinieux, G | 1 |
| Oudard, S | 1 |
| Dutrillaux, B | 1 |
| Poupon, MF | 1 |
| Puchner, MJ | 1 |
| Giese, A | 1 |
1 trial available for hypericin and Glioma
| Article | Year |
|---|---|
A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anthracenes; Antineoplastic Agents; Brain Neoplasms; | 2011 |
25 other studies available for hypericin and Glioma
| Article | Year |
|---|---|
Accumulation and penetration behavior of hypericin in glioma tumor spheroids studied by fluorescence microscopy and confocal fluorescence lifetime imaging microscopy.
Topics: Anthracenes; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Microscopy, Fluorescence; Perylene; | 2022 |
Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels.
Topics: Aniline Compounds; Anthracenes; Cell Line, Tumor; Cell Survival; Fluorescence; Glioma; Humans; Molec | 2019 |
Synergism between PKCδ regulators hypericin and rottlerin enhances apoptosis in U87 MG glioma cells after light stimulation.
Topics: Acetophenones; Angiogenesis Inhibitors; Anthracenes; Antineoplastic Agents; Apoptosis; Benzopyrans; | 2017 |
Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Glioma; Humans; Light; Perylene; Photochemotherapy; Photos | 2013 |
Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model.
Topics: Animals; Anthracenes; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Endoscopy; Glioma; | 2013 |
The role of anti-apoptotic protein kinase Cα in response to hypericin photodynamic therapy in U-87 MG cells.
Topics: Anthracenes; Apoptosis Regulatory Proteins; Cell Line, Tumor; Glioma; Humans; Perylene; Phosphorylat | 2014 |
Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
Topics: Adaptive Immunity; Animals; Anthracenes; Apoptosis; Brain Neoplasms; Cancer Vaccines; CD8-Positive T | 2016 |
Deeper insights into the drug defense of glioma cells against hydrophobic molecules.
Topics: Anthracenes; Anthraquinones; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tum | 2016 |
Estimation of PKCδ autophosphorylation in U87 MG glioma cells: combination of experimental, conceptual and numerical approaches.
Topics: Anthracenes; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Ceramides; Computer Simulation; Glio | 2017 |
Assessing light-independent effects of hypericin on cell viability, ultrastructure and metabolism in human glioma and endothelial cells.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Cell Respiration; Endothelial Cells; Glioma; Glycolysis; H | 2017 |
The flashlights on a distinct role of protein kinase C δ: Phosphorylation of regulatory and catalytic domain upon oxidative stress in glioma cells.
Topics: Algorithms; Anthracenes; Apoptosis; Brain Neoplasms; Catalytic Domain; Cell Line, Tumor; Glioma; Hum | 2017 |
Comment on "Hypericin uptake: a prognostic marker for survival in high-grade glioma".
Topics: Anthracenes; Brain Neoplasms; Glioma; Humans; Perylene | 2009 |
Interaction dynamics of hypericin with low-density lipoproteins and U87-MG cells.
Topics: Anthracenes; Cell Line, Tumor; Cell Membrane; Fluorescence; Glioma; Humans; Hydrophobic and Hydrophi | 2010 |
Selective enrichment of hypericin in malignant glioma: pioneering in vivo results.
Topics: Animals; Anthracenes; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Male; Neopla | 2011 |
Hypericin for visualization of high grade gliomas: first clinical experience.
Topics: Aged; Anthracenes; Brain Neoplasms; Female; Fluorescence; Glioma; Humans; Injections, Intravenous; M | 2012 |
Cell death response of U87 glioma cells on hypericin photoactivation is mediated by dynamics of hypericin subcellular distribution and its aggregation in cellular organelles.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Endocytosis; Fluorescence Resonance Energy Transfer; Gliom | 2012 |
Hypericin-an inhibitor of proteasome function.
Topics: Anthracenes; Antidepressive Agents; Electrophoretic Mobility Shift Assay; Glioma; Humans; Mammary Ne | 2005 |
Photodynamic therapy of malignant glioma with hypericin: comprehensive in vitro study in human glioblastoma cell lines.
Topics: Anthracenes; Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Glioblastoma; Glioma; Humans; Light; | 2007 |
Hypericin uptake: a prognostic marker for survival in high-grade glioma.
Topics: Adult; Aged; Anthracenes; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Diseas | 2008 |
Hypericin: a potential antiglioma therapy.
Topics: Anthracenes; Apoptosis; Brain Neoplasms; Cell Division; Cell Line; Cell Survival; DNA Damage; Dose-R | 1994 |
Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53.
Topics: Anthracenes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Ap | 1997 |
Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor.
Topics: Anthracenes; Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cells, Cultured; Enzyme Inhibito | 1997 |
Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro.
Topics: Anthracenes; Glioma; Humans; Perylene; Protein Kinase C; Radiation-Sensitizing Agents; Tumor Cells, | 1996 |
Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria.
Topics: Anthracenes; Apoptosis; Energy Metabolism; Enzyme Inhibitors; Glioma; Hexokinase; Humans; Hydrogen-I | 1998 |
Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation.
Topics: Anthracenes; Antineoplastic Agents, Hormonal; Cell Division; Cell Movement; Dose-Response Relationsh | 2000 |